IndustryCompany release

Relay Therapeutics reports Q3 loss of $81.7M, with cash funding operations into 2029

🇺🇸 Relay Therapeutics, Inc. (RLAY) · Wed 04 Nov 2026

The precision oncology company says Phase 3 breast cancer enrollment should finish in mid-2027, with updated vascular anomaly data due at ASH on 14 December.

Relay Therapeutics reported third-quarter 2026 results on 4 November, posting a net loss of $81.7 million. The company ended the period with $848.6 million in cash, which it expects to finance operations into 2029.

Its lead late-stage programme is the Phase 3 ReDiscover-2 trial, which tests zovegalisib plus fulvestrant in second-line HR+/HER2- breast cancer. Relay expects enrolment to be completed in mid-2027.

In vascular anomalies, updated data from the ReInspire study will be presented at the American Society of Hematology (ASH) meeting on 14 December. Relay said it will provide a regulatory update alongside the presentation. The summary does not specify what the update will cover.

Relay also noted that the US Food and Drug Administration has granted full approval to LYRFIGTU (lirafugratinib), a product of its partner Elevar, for FGFR2-rearranged cholangiocarcinoma. The company has hired a Head of Commercial and disclosed a preclinical, mutant-selective TIE2 inhibitor programme.

What it means for your team

  • The 14 December ASH presentation and accompanying regulatory update are the next milestone to watch for zovegalisib in vascular anomalies; details of any regulatory path have not yet been disclosed.
  • Mid-2027 enrolment completion for ReDiscover-2 sets the earliest timeline for a Phase 3 readout in second-line HR+/HER2- breast cancer; the source gives no readout date.
  • Full FDA approval of LYRFIGTU for FGFR2-rearranged cholangiocarcinoma is relevant to teams tracking targeted therapies and confirmatory evidence in biliary tract cancer.
  • The new commercial head hire suggests Relay is starting to build a market-access and launch function, though no launch timelines were given.

Company's press release (SEC filing): Relay Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Relay Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →